All these potential improvements are already being translated into a significant clinical benefit in HER2- positive metastatic breast cancer patients, as some of these new ADCs such as T-DXd and trastuzumab duocarmazine are already in an advanced phase of clinical development. Here, ERBB2 is linked to breast carcinoma.